Arya Mehrabanzad
Senior Associate
Get their honest, personalized take on your startup.
Sign in to pitch Arya →At a glance
- Full Name
- Arya Mehrabanzad
- Title
- Principal (previously listed as Vice President)
- Firm
- Ampersand Capital Partners
- Firm Type
- Growth-equity / private equity firm focused on healthcare and life sciences (not an angel/seed investor)
- Investment Stage
- Growth equity — majority and minority positions in established, revenue-generating companies (often as first institutional investor)
- Check Size
- ~$25–75 million equity per investment (firm-level range)
- Target Company Profile
- Life sciences / healthcare businesses, typically ~$10–100M revenue with positive EBITDA; founder-led companies with proven products or services poised to scale
- Sector Focus
- Laboratory products, laboratory/pharma services, contract manufacturing, specialty diagnostics and tools within healthcare & life sciences
- Geographic Focus
- North America, Europe, and APAC
- Location
- Boston, Massachusetts (One Post Office Square, Suite 2900)
Background
Arya Mehrabanzad is a Principal (previously Vice President) at Ampersand Capital Partners, a Boston-based private equity firm that has invested exclusively in the healthcare and life sciences sectors for more than 35 years. He joined Ampersand in 2016 and works on sourcing, evaluating, and supporting portfolio investments across the firm's core areas — laboratory products and services, pharma services, contract manufacturing, and specialty diagnostics.
Before joining Ampersand, Arya spent roughly three years at Health Advances, a strategy consulting firm dedicated to the healthcare industry, where he advised clients across the life sciences landscape. That combination of healthcare strategy consulting and buy-side investing underpins his focus on scaling scientifically-driven, revenue-generating businesses.
Arya holds an A.B. in Human Developmental and Regenerative Biology from Harvard University, giving him a scientific grounding well suited to Ampersand's life-sciences mandate. He has served on the boards of several Ampersand portfolio companies, including BioEcho Life Sciences, GenDx, Leinco Technologies, NanoImaging Services, and AnaBios.
Investment Thesis & Focus
- Invests through Ampersand's growth-equity strategy, not angel or seed rounds — targeting established life-sciences companies with real revenue (roughly $10–100M) and positive EBITDA.
- Takes both majority and minority positions, frequently as a company's first institutional investor, partnering with founders and management to accelerate growth.
- Firm-level equity checks generally run ~$25–75 million, deployed into organic growth plus "buy-and-build" M&A and transformative combinations.
- Sector concentration on laboratory products, laboratory/pharma services, contract manufacturing, and specialty diagnostics/tools — Ampersand describes backing "visionary founders with scientific innovations… poised for market success."
- Emphasis on post-investment value creation via active board engagement, sector expertise, and M&A support rather than passive capital.
Notable Investments
- BioEcho Life Sciences — German nucleic-acid extraction / sample-prep company; received a growth equity investment from Ampersand, with Arya joining the board.
- GenDx (Genome Diagnostics) — Netherlands-based transplant diagnostics (HLA typing) company; Ampersand board seat.
- Leinco Technologies — antibody and reagent manufacturer for research and diagnostics; board seat.
- NanoImaging Services — cryo-electron microscopy services provider for biopharma; board seat.
- AnaBios — human-tissue-based preclinical testing / drug safety company; board involvement.
- GeneWerk GmbH — genomics/gene-therapy analytics company that received an Ampersand growth investment (firm deal in his focus area).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.